Recombinant DNA Technology Market Size, Share and Global Trend By Product (Vaccines, Therapeutic Agents, Recombinant Protein, Others), By Component (Vectors, Expression System, Others), By Application (Diagnostics, Therapeutic, Food and Agriculture, Others), By End User (Biotechnology and Pharmaceutical Companies, Diagnostic Laboratories, Academic and Government Research Institutes, Other) and Regional Forecast, 2024-2032

Recombinant DNA technology has successfully established its dominance in the vaccines and medicines. Recombinant DNA technology is also being used for the diagnosis of diseases by the developing radioactive probes and diagnostic kits. In medicines, recombinant DNA technology can be employed for the production of antibiotics, hormones like insulins, enzymes, interferons, and many others. Recombinant DNA technology involves the isolation of the desired gene and introducing it into a vector DNA to enable the synthesis of the desired gene on a large scale.

Other than medicine, recombinant DNA technology also has application in the production of genetically modified crops and animals. The advantages of recombinant DNA technology in the treatment of chronic diseases such as diabetes, cancer, and others. Growing investment in research for the development of recombinant products, which is anticipated to fuel the recombinant DNA technology market growth during the forecast period.

Growing applications of recombinant DNA for the treatment of various diseases and the increased investment for research are the major factor responsible for the growth in recombinant DNA technology market. Apart from these, the rising trend of strategic mergers and acquisitions is also expected to boom the recombinant DNA technology market during the forecast period.

For example, in 2017, Sanofi Pasteur Inc., acquired Protein Sciences, which resulted in the addition of Flublok, an influenza vaccine into their product portfolio and strengthening both the position of Sanofi Pasteur Inc. as well as the global recombinant DNA technology market during the forecast period.

However, the ethical concerns and unknown outcomes of gene modifications are the factors that are likely to hamper the recombinant DNA technology market growth during the forecast period. 

Key Players Covered

Some of the major companies that are present in the global recombinant DNA technology market report include Novartis AG, Thermo Fisher Scientific Inc., Sanofi Pasteur Limited, Merck KGaA, Genentech Inc., GlaxoSmithKline plc., Eli Lilly and Company, Pfizer Inc., Janssen Pharmaceuticals Inc., and others.

SEGMENTATION

In terms of application, diagnostic application segment is anticipated to hold a considerable share in global recombinant DNA technology market owing to the growing number of genetic disorders and various cancers globally, enhancing the demand for early detection of disease in order to receive effective treatment therapies.

Key Insights

• Technological Advancements in recombinant DNA technologies


• The Regulatory Scenario of Key Country/Region


• Recent Key Industry Developments – Mergers, Acquisitions, And Partnerships.

Regional Analysis

The global recombinant DNA technologies market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the recombinant DNA technology market owing to the increase in strategic collaborations among many key players and rising R&D investments. In 2017, Novartis AG received FDA approval for its product based on gene transfer named Mariah for acute lymphoblastic leukemia, which is more likely to boost the recombinant DNA technology market in North America. Recombinant DNA technology market is anticipated to expand at a significant rate during the forecast period owing to the growing patient pool, growing investments by many government organizations, and rising awareness about the application of recombinant DNA technology in various sectors. 

Global Recombinant DNA Technology Industry Developments

• In July 2017, Sanofi Pasteur Limited acquired Protein Sciences, which resulted in addition of Flublok, an influenza vaccine into their product portfolio and strengthening both the position of Sanofi Pasteur Inc. as well as the global recombinant DNA technology market
• In 2017, Novartis AG received FDA approval for its product based on gene transfer named Mariah for acute lymphoblastic leukemia,